Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Teduglutide (Gattex/Revestive) peptide icon, one bubble per amino acidTeduglutide (Gattex/Revestive)33 residuesHGDGSFSDEMNTILDNLAARDFINWLIQTKITDEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Teduglutide (Gattex/Revestive)

Healing & RecoveryFDA Approved
2 h half-life·Injection

Also known as: Gattex, Revestive, ALX-0600

Sixty-three percent of patients cut their IV nutrition by at least a fifth in 24 weeks. Teduglutide (Gattex in the US, Revestive in Europe) is an FDA-approved GLP-2 receptor agonist that rebuilds the intestinal lining from the inside out, increasing villus height, crypt depth, and absorptive surface area in patients with short bowel syndrome. The important STEPS trial (n=86)[1] proved it works. The catch: list price runs $520,000 to $550,000 per year, mandatory colonoscopy surveillance comes with the prescription, and stopping the drug reverses the intestinal gains within weeks. SBS patients use it to reduce or eliminate dependence on parenteral nutrition.

What Is Teduglutide (Gattex/Revestive)?

Sixty-three percent response versus thirty percent on placebo. That single number from the STEPS trial (n=86)[1] carried teduglutide to FDA approval for short bowel syndrome with intestinal failure.

Teduglutide (Gattex, Revestive; CAS 197922-42-2) is a 33-amino acid recombinant analog of glucagon-like peptide-2. A single substitution at position 2 (alanine to glycine) blocks dipeptidyl peptidase-IV cleavage; that one change extends the half-life from roughly 7 minutes to about 2 hours. Enough for once-daily subcutaneous dosing.

The drug triggers intestinal mucosal growth by activating GLP-2 receptors on subepithelial myofibroblasts and enteric neurons. Villus height increases. Crypt depth increases. Absorptive surface area expands. The practical result: patients absorb more fluid and nutrients from the gut, so they can reduce or stop parenteral nutrition.

Long-term data backs this up. STEPS-2 [2] and STEPS-3 [3] confirmed sustained parenteral support reductions over 30 months of continuous treatment. In pediatric patients aged 1 year and older, Wales and colleagues (n=85)[4] reported an 82.1% response rate at 96 weeks. Both adults and children receive the same weight-based dose: 0.05 mg/kg/day.

The limitations are real. The STEPS trial enrolled only 86 patients. Cost runs $520,000 to $550,000 per year at list price. Colonoscopy surveillance is mandatory. And intestinal adaptation reverses within weeks of stopping, which means therapy is indefinite for most patients.

How Teduglutide (Gattex/Revestive) Works

Native GLP-2 lasts about 7 minutes in circulation before dipeptidyl peptidase-IV chews it apart. Teduglutide puts glycine in place of alanine at position 2, and that single amino acid change blocks the enzyme's cleavage site. Half-life jumps to approximately 2 hours.

Once injected subcutaneously (bioavailability around 88%, per Marier et al.)[5], teduglutide binds GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons. Receptor activation kicks off a trophic cascade: crypt cell proliferation accelerates, villus height and crypt depth increase, and new nutrient transporters appear on the mucosal surface. Mesenteric blood flow rises through nitric oxide-dependent vasodilation. Epithelial tight junctions tighten, improving barrier function.

Teduglutide also slows gastric emptying and dials down gastric acid secretion. Both effects give the shortened bowel more time to absorb what passes through it.

The net result is measurable. Plasma citrulline levels (a biomarker for enterocyte mass) start climbing within the first few weeks. By week 24 in the STEPS trial, 63% of patients on 0.05 mg/kg/day achieved at least a 20% reduction in weekly parenteral support volume. Peak plasma concentration hits between 3 and 5 hours post-injection, and the drug clears with a terminal half-life of roughly 2 hours (shorter in SBS patients, around 1.3 hours, likely due to altered distribution).

Teduglutide (Gattex/Revestive) Benefits

  • Teduglutide benefits center on restoring intestinal function and reducing dependence on intravenous nutrition in short bowel syndrome.
  • - The STEPS trial (n=86)[1] showed 63% of patients on 0.05 mg/kg/day achieved at least 20% reduction in weekly parenteral support volume at 24 weeks, compared with 30% on placebo (p=0.002). - Some patients reach complete enteral autonomy. Full independence from parenteral nutrition is the outcome SBS patients describe as life-changing in community reports. - Intestinal absorptive surface area physically increases through higher villus height, deeper crypts, and upregulated nutrient transporter expression. - Pediatric patients respond even better. Wales et al. (n=85)[4] found an 82.1% response rate at 96 weeks in children aged 1 year and older, with a mean parenteral fluid reduction of 30.1 mL/kg/day. - Quality of life improves in a way that's hard to quantify on paper. Fewer hours tethered to an IV pole means sleeping through the night, traveling, and returning to work. - Long-term durability is confirmed. STEPS-3 [3] showed sustained benefit at 30 months of continuous treatment with no signal of efficacy fade.

Teduglutide (Gattex/Revestive): Science vs Community Consensus

Aligned
Scientific Evidence
Strong
Based on 9 key studies·FDA-approved

FDA-approved GLP-2 receptor agonist for SBS-associated intestinal failure with strong RCT evidence.

Dosing studied: 0.05 mg/kg/day SC once daily (adult and pediatric ≥1 year, normal renal function) | 0.025 mg/kg/day if eGFR <60 mL/min/1.73m²
Read the evidence (key study, limitations)

STEPS trial (n=86): 63% achieved ≥20% reduction in weekly parenteral support volume at 24 weeks vs. 30% placebo (p=0.002). Long-term STEPS-2/3 data confirm sustained efficacy at 30+ months. Pediatric Wales et al. 2024 (n=85): 82.1% response rate at week 96 in children ≥1 year.

Key Study

Jeppesen et al., Gastroenterology 2012 (PMID 22982184): STEPS RCT (n=86); 63% vs. 30% placebo response at 24 weeks (p=0.002)

Limitations

Small trial (n=86 STEPS); rare disease limits head-to-head RCT data; colonoscopy surveillance burden; prohibitive cost ($520K–$550K/year) limits real-world access; no data on off-label use; regression of intestinal adaptation upon discontinuation requires indefinite therapy

Community Experience
Weak
4.5/5
Based on n≈6 Drugs.com reviews (9.3/10, 83% positive)

Highly positive among the small SBS patient community.

Community dosing: 0.05 mg/kg/day per FDA label: no community dose variation; patients follow prescribed weight-based dose
Read the reports (what users report 5, common issues 5)

Life-changing reduction or elimination of TPN dependence is the dominant reported outcome. Main barriers are cost/insurance access and colonoscopy requirement, not tolerability. No off-label or performance community use documented.

What users report (5)
  • Life-changing freedom from or major reduction in TPN hours (reported by virtually all responding patients)
  • Significant quality-of-life improvement: fewer hours tethered to IV lines
  • Increased lean body mass and improved nutritional markers
  • Some patients achieve complete enteral autonomy (full TPN independence)
  • Results continue improving beyond 24 weeks, often plateauing at 12+ months
Common issues (5)
  • Extreme cost ($520K–$550K/year list price) and insurance prior authorization burden
  • Abdominal pain and distension most common early side effects
  • Mandatory colonoscopy pre-treatment and at 1 year adds procedural burden
  • Injection site reactions (redness, swelling) without strict site rotation
  • Regression of intestinal adaptation within weeks of stopping: perceived as permanent dependency
Science & Community Aligned

SBS patients using teduglutide are the clinical trial population: there is no off-label community. Scientific evidence and patient community both report strong efficacy with TPN reduction as the primary outcome. Community concerns (cost, colonoscopy burden, abdominal side effects) are consistent with the clinical safety and access literature. No dose discrepancy exists: patients follow the FDA-approved 0.05 mg/kg/day weight-based dose.

Teduglutide (Gattex/Revestive) Dosage Guide

FDA LabelGattex/Revestive (teduglutide) FDA Prescribing Information (n=86 (STEPS trial))Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner50 mcg/kgDaily
Moderate50 mcg/kgDaily
Aggressive50 mcg/kgDaily
Note:

Teduglutide is supplied as a 5 mg lyophilized vial in 30-vial kits. Reconstitute with the 0.5 mL sterile water for injection included in the kit. Do not use bacteriostatic water. Gently roll the vial; do not shake. Let it sit 30 seconds before drawing.

That gives you a 10 mg/mL concentration. For a 70 kg patient at the standard 0.05 mg/kg/day dose, you need 3,500 mcg (3.5 mg), which is 0.35 mL or 35 units on a 100-unit insulin syringe. A 50 kg patient draws 25 units (2,500 mcg). A 100 kg patient needs 5,000 mcg (0.5 mL), but only 0.38 mL (3.8 mg) can be drawn from one vial (GATTEX label, section 2.6). At the standard dose, anyone over 76 kg needs more than 3.8 mg, so more than one vial; the prescriber says how many.

The non-obvious thing beginners miss: you must use each reconstituted vial within 3 hours. There are no preservatives. Don't prepare vials ahead of time. Bedtime dosing is the community favorite because it helps you sleep through the early abdominal bloating instead of sitting with it all day. Rotate injection sites across four abdominal quadrants; mark the quadrant on the vial if it helps you track rotation.

Cycling

No scheduled off period.

Teduglutide is used continuously as a chronic therapy. There is no cycling protocol: the drug is administered daily without breaks. Discontinuation leads to regression of intestinal adaptation within weeks. Regular colonoscopy surveillance and lipase/amylase monitoring every 6 months are required during ongoing therapy. Clinical reassessment of parenteral support needs should occur at least every 6 months.

Calculate your Teduglutide (Gattex/Revestive) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Teduglutide (Gattex/Revestive) Protocols by Goal

intermediateFDA LabelIndefinite continuous therapy (no off periods)
Initiation
Wk 1–4
0.05 mg/kg/day (absolute dose: ~2,500 mcg for 50 kg; ~3,500 mcg for 70 kg; ~5,000 mcg for 100 kg) · Once daily · Subcutaneous injection
Early Adaptation
Wk 5–12
0.05 mg/kg/day (unchanged) · Once daily · Subcutaneous injection
Optimization
Wk 13–24
0.05 mg/kg/day (unchanged) · Once daily · Subcutaneous injection
Maintenance
Wk 24+ (indefinite)
0.05 mg/kg/day (unchanged) · Once daily · Subcutaneous injection

Expected: 63% response rate (≥20% PS reduction) at 24 weeks; continued improvement at 12+ months; some patients achieve complete TPN independence

Monitor: Colonoscopy: pre-treatment + 1 year post-initiation + every 5 years thereafter. Lipase/amylase + bilirubin every 6 months. Urine output daily (guides PS reduction timing). Monitor oral narrow-therapeutic-index drug levels (warfarin INR, cyclosporine, tacrolimus, levothyroxine TSH). Assess for fluid overload as PS volumes are weaned.

How to Inject Teduglutide (Gattex/Revestive)

  1. 1
    Step 1

    Pull one 5 mg teduglutide vial and the supplied 0.5 mL sterile water for injection from the refrigerator. Let both reach room temperature (about 15 minutes, or briefly hold the vial in your palm).

  2. 2
    Inject all 0.5 mL of sterile water into the vial

    Gently roll between your palms for about 15 seconds. Do not shake. Let the vial stand for 30 seconds to allow complete dissolution.

  3. 3
    Calculate your dose based on body weight at 0.05 mg/kg/day

    The reconstituted concentration is 10 mg/mL. A 50 kg patient needs 0.25 mL (25 units on a 100-unit insulin syringe). A 70 kg patient needs 0.35 mL (35 units). A 100 kg patient needs 0.5 mL (50 units), more than the 0.38 mL one vial can give (label section 2.6), so that dose takes two vials. For renal impairment (eGFR under 60), cut the dose in half: 0.025 mg/kg/day.

  4. 4
    Step 4

    Draw the calculated volume into a 29 or 30 gauge insulin syringe. Tap out air bubbles and push to the correct mark.

  5. 5
    Step 5

    Inject subcutaneously into the abdomen, rotating across four quadrants daily. Thigh and upper arm are alternatives. Optional: ice the site for 30 to 60 seconds before injection to reduce sting.

  6. 6
    Inject at the same time each day

    Bedtime is commonly preferred.

  7. 7
    Discard any unused reconstituted solution immediately

    There are no preservatives, and the solution is not stable beyond 3 hours.

Teduglutide (Gattex/Revestive) Stacking Protocols

Works With

Avoid

Oral anticoagulants (warfarin)

Teduglutide increases intestinal absorption: enhanced warfarin absorption may significantly raise INR and bleeding risk. Monitor INR closely; dose adjustments likely needed.

Immunosuppressants (cyclosporine, tacrolimus)

Enhanced GI absorption may increase cyclosporine/tacrolimus levels and toxicity risk. Monitor drug levels closely when starting or adjusting teduglutide dose.

Estimated Cost

Brand Price
~$43,141/month (~$520,000–$550,000/year at list price; weight-dependent: 100 kg patients cost ~2x 50 kg patients). Takeda patient assistance: $0 co-pay up to $20,000/year for eligible patients.

Pricing updated 2026-04-09

Teduglutide (Gattex/Revestive) Side Effects

Gattex has no boxed warning. Its label lists five warnings and precautions instead (section 5), led by acceleration of neoplastic growth. Based on the drug's growth effect on gut tissue and on rodent tumor findings, the label says teduglutide may cause hyperplastic changes, including neoplasia.

In 2-year studies, male rats developed more bile duct and jejunal adenomas, and mice more gallbladder papillary adenomas. Male mice on the highest dose also developed jejunal adenocarcinomas.

In the adult trials, 14 patients had GI tract polyps found after starting treatment. Three men were diagnosed with cancer; two had long smoking histories and lung cancer.

Adults need a colonoscopy and upper GI endoscopy within 6 months before the first dose, with any polyps removed. Both are repeated at the end of year 1. After that, it's at least every 5 years if no polyp turns up, or standard polyp follow-up if one does.

Children get a fecal occult blood test before starting and every year after. New or unexplained blood in the stool triggers a colonoscopy or sigmoidoscopy plus an upper GI endoscopy. A colonoscopy or sigmoidoscopy also follows after 1 year, then every 5 years.

A cancer of the GI tract, liver, gallbladder, bile ducts or pancreas means stopping teduglutide. For a cancer elsewhere, continuing is a benefit-risk call. For people already at higher cancer risk, the label says to use it only if the benefits outweigh the risks.

Intestinal obstruction, the second warning, hit 3 of 77 patients (4%) on the label dose in the 24-week placebo-controlled trials, and none on placebo. Teduglutide is paused while a blockage is managed and can restart once it clears. Patients with a stoma had more stoma complications, 42% vs 14% on placebo.

Third come gallbladder, bile duct and pancreas disease. Cholecystitis, cholangitis, gallstones and pancreatitis were all reported in trials. The label calls for bilirubin, alkaline phosphatase, lipase and amylase within 6 months before starting, then at least every 6 months.

Fluid overload is the fourth warning. As the gut absorbs more fluid, parenteral support may need to come down. In the placebo-controlled trials, fluid overload (edema included) hit 12% vs 7% on placebo, and 2 patients on teduglutide developed congestive heart failure.

Stopping can swing the other way, into fluid and electrolyte imbalance, so those need checks after the last dose.

The fifth warning covers oral drugs, since teduglutide can increase how much of them gets absorbed. One trial patient on the benzodiazepine prazepam fell into a coma in the first week; it resolved 5 days after both drugs stopped. Oral drugs that need titration or have a narrow therapeutic index call for monitoring, and their dose may need to drop.

Common reactions come from the placebo-controlled trials, with 77 adults on the label dose. Abdominal pain led at 30% (22% on placebo), and nausea hit 23% (20%). Upper respiratory tract infection reached 21% (12%), while abdominal distension showed the widest gap, 20% vs 2%.

Injection site reactions ran 13% (12% on placebo), vomiting 12% (10%), and hypersensitivity such as rash or itching 10% (7%). The label recommends rotating injection sites across the abdomen, thighs and upper arms. In 41 children aged 1 to under 17, the safety profile was similar to that in adults.

In pregnancy, case reports haven't identified a drug-linked risk. Rat and rabbit studies found no embryo-fetal harm at up to 686 and 657 times human exposure. Breastfeeding isn't recommended during treatment; the label cites possible serious reactions in the infant, including tumorigenicity.

Call the prescriber right away for abdominal pain or swelling, trouble passing stool or gas, vomiting, or a swollen or blocked stoma. The same goes for fever, chills, dark urine, yellowing skin or eyes, swollen ankles, fast weight gain or trouble breathing.

Common Issues & Solutions

Abdominal pain and distension weeks 1–6: typically transient trophic response: reduce PS volumes as tolerated and continue therapy; persistent severe pain warrants intestinal obstruction workup

Fluid overload as absorption improves: common if PS volumes are not proactively reduced; use urine output increase (≥1 mL/kg/day above baseline) as trigger to reduce PS by 10–20%

No response at week 24 (<20% PS reduction): confirm injection technique and site rotation; verify compliance; check for concurrent infection or metabolic issue; colon-in-continuity patients have higher response rates: its absence may explain non-response

Reconstitution errors: use ONLY the 0.5 mL sterile water for injection supplied in the kit: do NOT use bacteriostatic water (contains benzyl alcohol); gently roll vial (do not shake); allow 30 seconds before drawing; discard unused reconstituted solution within 3 hours

Injection site reactions (redness, nodule formation): rotate strictly across all 4 abdominal quadrants; allow site to reach room temperature; apply ice 30–60 seconds before injection

Ask AI about this page

Ask AI for a second opinion on Teduglutide (Gattex/Revestive) dosing and side effects

Contraindications

  • Gattex label: no contraindications (section 4); the items here are its section 5 warnings plus its pregnancy and breastfeeding guidance (section 8)
  • Gastrointestinal cancer (GI tract, liver, gallbladder, bile ducts, pancreas): stop teduglutide if one develops; for other cancers, continuing is a benefit-risk decision (section 5.1)
  • Higher cancer risk, including a cancer history: use teduglutide only if the benefits outweigh the risks (section 5.1)
  • Polyps: adults need a colonoscopy and upper GI endoscopy within 6 months before starting, with polyps removed; children get a fecal occult blood test first (section 5.1)
  • Intestinal or stomal obstruction: pause teduglutide while it is managed; it can restart once the obstruction resolves, if clinically indicated (section 5.2)
  • Gallbladder, bile duct or pancreatic disease: check bilirubin, alkaline phosphatase, lipase and amylase within 6 months before starting, then at least every 6 months (section 5.3)
  • Cardiovascular disease: fluid overload and congestive heart failure occurred in trials; if fluid overload occurs, adjust parenteral support and reassess teduglutide, especially with underlying cardiovascular disease (section 5.4)
  • Pregnancy: the Medication Guide says it is not known if Gattex will harm an unborn baby and to tell the prescriber right away about a pregnancy; case reports have not identified a drug-linked risk, and rat and rabbit studies found no embryo-fetal harm (section 8.1)
  • Breastfeeding: not recommended during treatment (section 8.2)

Drug Interactions

  • Oral medications with narrow therapeutic index: teduglutide increases intestinal absorption and may raise serum levels of concomitant oral drugs; dose adjustments may be needed
  • Benzodiazepines and other CNS depressants: increased oral absorption may potentiate sedative effects
  • Oral anticoagulants (warfarin): enhanced absorption may increase INR; monitor closely
  • Immunosuppressants (cyclosporine, tacrolimus): enhanced absorption may increase toxicity risk; monitor drug levels
  • Diuretics and fluid-balance medications: as intestinal absorption improves, parenteral fluid needs decrease; adjust accordingly to avoid fluid overload
  • Thyroid medications (levothyroxine): absorption may be altered; monitor TSH levels
  • Enhanced GI absorption may increase cyclosporine/tacrolimus levels and toxicity risk. Monitor drug levels closely when starting or adjusting teduglutide dose.

Product Quality

Recommended Monitoring

TestWhenTarget
ColonoscopyWithin 6 months before initiation (adult); at 1 year post-initiation; every 5 years thereafter. Pediatric: fecal occult blood pre-treatment; colonoscopy at 1 year.No polyps (must be removed pre-treatment); no malignancy (mandatory discontinuation if detected)
Serum lipase and amylase (± bilirubin)Baseline; every 6 monthsWithin normal limits; >3x ULN warrants therapy reassessment
Urine outputDaily during active PS weaning (weeks 5–24+)≥1 mL/kg/day increase above baseline → reduce PS by 10–20%
Renal function (eGFR / serum creatinine)Baseline; every 6–12 months or with clinical changeseGFR ≥60: standard dose. eGFR <60: reduce to 0.025 mg/kg/day
Oral narrow-therapeutic-index drug levelsAt initiation and during significant PS weaning changesPer individual drug therapeutic range
Fluid and electrolyte statusOngoing during PS weaning; at each clinical assessmentNo edema, normal electrolytes, stable cardiopulmonary status
Growth and nutritional status (pediatric)Throughout treatment in children, especially while parenteral support is being reducedWeight-for-age and BMI Z-scores holding steady from baseline
Colonoscopy

Intestinal trophic effects could theoretically accelerate neoplastic growth; surveillance is mandatory per FDA label

Serum lipase and amylase (± bilirubin)

GLP-2 receptor activation has trophic effects on pancreatic and biliary tissue; biliary/pancreatic disease risk requires surveillance

Urine output

Increase of ≥1 mL/kg/day above baseline is the clinical trigger for PS volume reduction; without monitoring, fluid overload risk

Renal function (eGFR / serum creatinine)

eGFR <60 mL/min/1.73m² requires 50% dose reduction to avoid 2.6x AUC accumulation

Oral narrow-therapeutic-index drug levels

Improved intestinal absorption may increase serum levels of warfarin (INR), cyclosporine, tacrolimus, levothyroxine (TSH)

Fluid and electrolyte status

Failure to reduce PS as intestinal fluid absorption improves causes fluid overload and potential CHF exacerbation

Growth and nutritional status (pediatric)

A US registry of 140 children (PMID 42754721) saw the modeled share with low weight-for-age Z-scores rise from 2.3% at baseline to 12.7% at 3 years (p<0.01). Mean BMI Z-scores also fell while parenteral calories dropped 49.5%; height did not decline. The authors recommend careful attention to nutritional status.

Teduglutide (Gattex/Revestive) Before and After

Weeks 1-4

Treatment initiation at 0.05 mg/kg/day. GI side effects (abdominal pain, nausea, distension) are most common early and typically mild-moderate. Parenteral support volumes are maintained while intestinal adaptation begins. Plasma citrulline levels may start rising, indicating enterocyte mass expansion.

Weeks 5-12

Intestinal absorption capacity begins increasing measurably. First parenteral support volume reductions (10-20%) may be attempted based on urine output monitoring. Villus height and crypt depth begin increasing. GI side effects generally stabilize or improve.

Weeks 13-24

Peak response period aligned with the STEPS trial endpoint. 63% of patients achieve ≥20% reduction in weekly parenteral support volume. Some patients may achieve complete days off parenteral nutrition. Lean body mass and nutritional markers improve. Continued monitoring for fluid balance is essential.

Weeks 24-52

Sustained and often progressive reductions in parenteral support. STEPS-2 data show continued improvement beyond 24 weeks. Some patients achieve enteral autonomy (complete freedom from parenteral nutrition). Colonoscopy surveillance should be scheduled per protocol.

Year 2+

Long-term maintenance therapy with sustained benefits. STEPS-3 data confirm durability of response over 30+ months. Parenteral support reductions are maintained. Ongoing monitoring includes biannual lipase/amylase and periodic colonoscopy. Regression of adaptation occurs if therapy is discontinued.

What to Expect

Weeks 1 through 4: Treatment starts at 0.05 mg/kg/day. GI side effects are most common in this window, particularly abdominal pain, nausea (about 31% over the long term), and distension. Parenteral support volumes stay unchanged while the intestinal lining begins adapting internally. Plasma citrulline may start rising, which signals enterocyte mass is expanding. Bedtime dosing helps you sleep through the bloating.

Weeks 5 through 12: Intestinal absorption capacity starts increasing measurably. If urine output has climbed at least 1 mL/kg/day above baseline, clinicians typically attempt the first parenteral support reductions of 10 to 20%. Villus height and crypt depth begin increasing histologically. GI side effects generally stabilize by week 6 to 8. Cautious optimism is the phrase that fits this window best.

Weeks 13 through 24: This is the peak response window, matching the STEPS trial's primary endpoint. Sixty-three percent of teduglutide patients achieved at least a 20% reduction in weekly parenteral support volume (versus 30% on placebo). Some patients reach complete days off parenteral nutrition. Lean body mass and nutritional markers improve. Fluid management becomes the most active clinical issue, not side effects. Month 6 bloodwork (lipase and amylase) is due.

Weeks 24 through 52: Benefits continue building. STEPS-2 data confirm continued parenteral support reduction beyond 24 weeks. Some patients achieve full enteral autonomy, which is the outcome community members describe as the most life-changing. The 1-year colonoscopy is due per protocol. Patients who responded keep improving; many don't plateau until 12 to 18 months.

Year 2 and beyond: Long-term maintenance therapy with stable benefit. STEPS-3 [3] confirms durability at 30 months and beyond. Parenteral support reductions hold. Ongoing monitoring includes lipase and amylase every 6 months and colonoscopy at least every 5 years. The key long-term patient concern isn't side effects; it's insurance coverage continuity and annual prior authorization renewal. Stopping treatment causes intestinal adaptation to regress within weeks.

Detailed Timeline: Science vs Community

Weeks 1–4
Science

Intestinal mucosal adaptation begins; plasma citrulline levels start rising (early biomarker of enterocyte mass expansion). GI side effects most prevalent in this window. No PS reductions yet.

Community

Abdominal pain, bloating, and nausea in first 2–4 weeks. No change in PS requirements: expected. Bedtime dosing reduces awareness of bloating.

Weeks 5–12
Science

Measurable increases in intestinal absorptive capacity. First PS volume reductions (10–20%) may be attempted if urine output increases ≥1 mL/kg/day above baseline. Villus height and crypt depth begin increasing histologically.

Community

First signs of improvement. Some patients begin reducing PS days or volumes. GI side effects stabilize. Cautious optimism.

Weeks 13–24
Science

63% of teduglutide patients achieve ≥20% weekly PS volume reduction (vs. 30% placebo). Lean body mass and nutritional markers improve. Some patients achieve complete days off TPN.

Community

Clear changes in PS volume and/or infusion days. Colon-in-continuity patients may approach TPN-free days. Month 6 biannual bloodwork (lipase/amylase).

Weeks 24–52
Science

STEPS-2 data: continued PS reduction beyond 24 weeks. Some patients achieve enteral autonomy. Annual colonoscopy due at 1 year post-initiation.

Community

Patients who responded continue improving; plateau may not be reached until 12–18 months. Complete TPN independence is most life-changing reported outcome. Upcoming 1-year colonoscopy.

Year 2+
Science

STEPS-3: durability confirmed at 30+ months. Adaptation regresses within weeks of discontinuation: indefinite therapy required.

Community

Stable PS reduction on continuous therapy. Key long-term concern: insurance coverage continuity and annual authorization renewal.

Pharmacokinetics

Half-Life
2h
Bioavailability
SC: ~88%
Tmax
3-5 hours
Data Confidence
high

Source: FDA Prescribing Information (Gattex), Section 12.3; Marier et al. J Clin Pharmacol 2010 PMID:19773525

Pharmacokinetics: Active Dose Over Time

t½ = ~2 hours (1.3h in SBS patients; range 0.9-3h depending on body weight)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
33
Sequence
HGDGSFSDEMNTILDNLAARDFINWLIQTKITD
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Teduglutide (Gattex/Revestive)

  • Adults with short bowel syndrome-associated intestinal failure dependent on parenteral support
  • Pediatric patients (≥1 year) with SBS-associated intestinal failure requiring parenteral support
  • Post-surgical SBS patients following massive intestinal resection
  • Patients with Crohn's disease-related SBS requiring parenteral nutrition
  • SBS patients seeking to reduce hours of parenteral support and improve quality of life
  • Patients with intact colon-in-continuity (higher response rates observed in this subgroup)

Related Peptides

What Changed for Teduglutide (Gattex/Revestive)

  1. Safety

    Corrected Oct 14, 2026: Gattex has no boxed warning; the teduglutide side effects now follow its five label warnings and trial rates, per the Gattex label.

    Before: A "boxed-style warning" for neoplastic growth, teratogenic effects in animal studies, stopping for any cancer, headache in about 35% and a nephrolithiasis signal After: No boxed warning. The five section 5 warnings (neoplastic growth, obstruction, biliary and pancreatic disease, fluid overload, oral drug absorption), label trial rates, stopping for GI cancers

    What this does not mean: The tumor-growth warning stands, with screening before and during treatment. The side effects had cited birth defects in animals (the label found no embryo-fetal harm), a kidney stone signal and a 35% headache rate; the label gives none.

    Source: Gattex (teduglutide) prescribing information (openFDA label record, SPL version 20, effective Sep 5, 2025) (opens in a new tab) · Saved copy

  2. Safety

    Corrected Oct 14, 2026: Gattex lists no contraindications; the teduglutide list now carries its warnings and no animal birth-defect claim, per the Gattex label.

    Before: Active GI cancer listed as a contraindication, a 5-year GI cancer history rule, known hypersensitivity, and "teratogenic effects observed in animal studies" for pregnancy After: No label contraindications. Section 5 warnings (stop for GI cancer, polyps, obstruction, biliary and pancreatic disease, fluid overload), no embryo-fetal harm in animals, breastfeeding not recommended

    What this does not mean: Stopping for a GI cancer, polyp removal before starting and the lab checks still apply as label warnings. The list had called GI cancer a contraindication and added a 5-year cancer rule and a hypersensitivity line.

    Source: Gattex (teduglutide) prescribing information (openFDA label record, SPL version 20, effective Sep 5, 2025) (opens in a new tab) · Saved copy

  3. Dosing

    Corrected Oct 9, 2026: every teduglutide tier is the one label dose, 50 mcg/kg (0.05 mg/kg) daily, not a flat 2.5 to 5 mg, per the Gattex label.

    Before: Tiers of 2,500, 3,500 and 5,000 mcg daily (the 0.05 mg/kg dose worked out for 50, 70 and 100 kg) After: Every tier 50 mcg/kg (0.05 mg/kg) once daily, the label dose for adults and children

    Source: Gattex (teduglutide) prescribing information (openFDA label record, SPL version 20, effective Sep 5, 2025) (opens in a new tab) · Saved copy

  4. Safety

    In a US registry of 140 children on teduglutide, the share with low weight-for-age rose from 2.3% to 12.7% by year 3, published Sep 17, 2026, per Pediatr Res.

    What this does not mean: A registry with no comparison group, so the drug is not shown to cause it. Parenteral calories fell 49.5% by year 3; the authors advise watching nutrition.

    Source: Pediatr Res 2026, Safety and long-term effectiveness of teduglutide in children with intestinal failure (NCT04832087) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  5. Safety

    FDA ended the Gattex (teduglutide) REMS safety program on Aug 26, 2026, finding it no longer necessary, per FDA's letter on NDA 203441 supplement 28.

    What this does not mean: The risks it covered still apply: possible tumor and polyp growth, bowel blockage, and gallbladder, bile duct and pancreas problems. FDA found specialists wrote about 80% of 2020-2024 prescriptions.

    Source: FDA supplement approval letter, Gattex (teduglutide) NDA 203441/S-28, Aug 26, 2026: "a REMS is no longer required for Gattex" (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

References

  1. [1]Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS, Jeppesen et al., Gastroenterology 2012) (opens in a new tab)(n=86)PubMed (opens in a new tab)PubMed
  2. [2]Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome (STEPS-2) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure (Wales et al., J Pediatr Gastroenterol Nutr 2024) (opens in a new tab)(n=85,)PubMed (opens in a new tab)PubMed
  5. [5]Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Safety and long-term effectiveness of teduglutide in children with intestinal failure: multicenter post-marketing registry (Pediatr Res 2026) (opens in a new tab)(n=140)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C (36-46°F) in original carton. Do not freeze. Protect from light.
After Reconstitution
Use within 3 hours of reconstitution. Keep refrigerated if not used immediately. Do not freeze reconstituted solution.
Temperature
2-8°C (36-46°F); may store at room temperature up to 25°C (77°F) for up to 4 weeks after dispensing

Frequently Asked Questions

Teduglutide has one approved dose, 0.05 mg/kg (50 mcg/kg) once daily, and every tier shows it. Short bowel syndrome patients get the same per-kg dose whatever the severity. Your daily amount scales with body weight: about 2,500 mcg at 50 kg, 3,500 mcg at 70 kg and 5,000 mcg at 100 kg.

First reductions in parenteral support volume (10-20%) can be attempted as early as weeks 5-12, based on urine output monitoring. The primary endpoint in the STEPS trial was at 24 weeks, when 63% of teduglutide patients achieved at least 20% reduction in weekly PS volume vs 30% on placebo. Complete TPN independence was achieved in some patients in long-term extensions.

The FDA label requires a 50% dose reduction (to 0.025 mg/kg/day) for moderate-to-severe renal impairment (eGFR under 60) or end-stage renal disease. A dedicated PK study showed 2.1x higher peak levels and 2.6x higher total exposure in ESRD patients. That's a dose adjustment, not a contraindication.

Colonoscopy must be done within 6 months before starting. Repeat at 1 year post-initiation, then at least every 5 years. Any colorectal polyps must be removed before you begin. If malignancy is found, stop teduglutide. The requirement exists because the drug's trophic effects on gut tissue could theoretically accelerate neoplastic growth.

No. While GLP-2 is gut-trophic and the STEPS trial showed lean mass increases, those reflect correction of SBS malabsorption, not muscle-building. The prohibitive cost and mandatory colonoscopy surveillance have prevented any grey-market adoption. BPC-157 fills the "gut healing peptide" niche in performance communities instead.